Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
Elan Fall 2013
Next
Download to read offline and view in fullscreen.

1

Share

Download to read offline

Innovative medicine initiative 2

Download to read offline

Presentation given at Health Chalenges Congress 2016. International Congress Centre, Katowcie, Poland

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Innovative medicine initiative 2

  1. 1. INNOVATIVE MEDICINE INITIATIVE 2 Presentation by Kazik Anhalt Gateopen Innovation Management
  2. 2. HORIZON 2020 Health, Demographic Change and Wellbeing:  improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease;  improve our ability to monitor health and to prevent, detect, treat and manage disease;  support older persons to remain active and healthy; test and demonstrate new models and tools for health and care delivery; Budget in total: 7 471,8 bln EUR
  3. 3. PUBLIC- PRIVATE PARTNERSHIP  Legal base: Article 187TfEU ,,The Union may set up joint undertakings or any other structure necessary for the efficient execution of Union research, technological development and demonstration programmes”  Structure: European Commission (EC) and pharmaceutical industry European Federation of Pharmaceutical Industries Federation (EFPIA)  Finance: Horizon 2020 and private contribution in kind; €3.3 bilion in total for the period 2014-2024 EC @ €1.638 bln EUR + EFPIA @ €1.425 bln EUR + life science assocciations & Associates @ €213 mln
  4. 4. EFPIA
  5. 5. STRATEGIC RESEARCH AGENDA 2014-2024 Four major axes of research:  target validation and biomarker research (efficacy and safety);  adoption of innovative clinical trial paradigms;  innovative medicines;  patient-tailored adherence programmes
  6. 6. THE PRIORITIES (12) • respiratory diseases; • immune-mediated diseases; • ageing-associated diseases; • cancer; • rare/orphan diseases; • vaccines. • antimicrobial resistance; • osteoarthritis; • cardiovascular diseases; • diabetes; • neurodegenerative diseases; • psychiatric diseases;
  7. 7. GOVERNANCE STRUCTURE European Commission (5) EFPIA (5) Assocciated Partner (0) Governing Board (10) States Representative Group (SRG) Strategic opinions Executive Director (ExD) Programme Office (PO) ScientificCommitte (SC) 11 + 3 ad hoc Scientific advise Nominate 3 SC Members Report
  8. 8. IMI DO’S  H2020Work Programme 2016- 2017 influence  ,,Internal’’ H2020 RDI projects with largest actors within the health sector  SME’s networking within consortia  Open Innovation (cooperation and knowledge sharing)  Open new commercial possibilities based on new services and products  SME 100% financing  Provide research infrastructure  Assisst start-ups with potential to develop
  9. 9. NATIONAL SMART SPECIALIZATIONS (KIS)  KIS 1. Medical engeenering technologies and biomedicine  KIS 2. Diagnostics and civilization related diseases therapy and personalized medicine  KIS 3. Paramedical products (health lifestyle and beauty) Purpose: Only projects related to KIS are to be qualified for NCBiR financial support
  10. 10. PROGRAMMES SYNERGY EU Innitiatives and Programmes (IMI2, EIT, H2020) NCBiR Programmes (InnoMed, StrategMed) Regional Operation Programmes (RPO) Cross- financing and financing vehicles for EU level accession ?National Smart Specialization
  11. 11. INNOVATION HEALTH ECOSYSTEM -POTENTIAL SYNERGY- National Centre for Research and Development (NCBiR) strategic programme StrategMed & InnoMed Polish Agency for Enterprise and Development (PARP) 2.3.3 axe for internationalization of national key clusters Regional Operational Programme  9.2.3 RPO WŚ Increase of access to health related services in Region  8.3 (Enhancement of access to prevention, diagnostics and rehabilitation that facilitate stable employment and return to work  Działanie 1.2 (RDI in SME)
  12. 12. NCBIR STRATEGMED III CALL Topics: Cardiology and cardiosurgery Oncology Budget allocation: 115 mln PLN Type of innitiatve: up- bottom (government driven) Internationalization of innovation: Influence index S1W1 (increase of participation in Horizon 2020); S2W1 (increase of grant aborption @ H2020 or ERC); S3W1 Neurology and senses Regenerative medicine
  13. 13. VOICE FROM POLAND ,,Research priorities of IMI2 are simultaneously aligned to tose ofWHO and concern plethora of challenges- too large and perplexed that one company, one university or even one country could cope with” Polish ex-member of State Representative Group
  14. 14. VOICE FROM IMI2 ,,Given the great science and technology being developed in Poland, there is no reason why Polish teams should not be part of IMI consortia. Interested parties should find out who is applying (SRG network) and try to join. Also for SMEs - they are eligible for 100 per cent funding in IMI 2” Especially for Medinvest Scanner: Pierre Meulien Executive Director of IMI2
  15. 15. THANKS FORYOUR ATTENTION Innovate creation, create innovation! Kazik_Anhalt@yahoo.com Contact me for more @:
  • MeyirzhanYerman

    Jul. 16, 2018

Presentation given at Health Chalenges Congress 2016. International Congress Centre, Katowcie, Poland

Views

Total views

326

On Slideshare

0

From embeds

0

Number of embeds

6

Actions

Downloads

6

Shares

0

Comments

0

Likes

1

×